Chagas disease, or American trypanosomiasis, is a tropical parasitic disease caused by the flagellate protozoan Trypanosoma cruzi (T. cruzi). Considered a neglected tropical disease or disease of poverty, Chagas is endemic in 21 countries of the Americas. The T. cruzi is transmitted to humans and other mammals by a vector insect, the blood-sucking bugs of the subfamily Triatominae, popularly known as the conenose bugs and kissing bugs. The triatomine bugs are capable of colonizing poorly constructed homes in rural, suburban and urban areas.
Chagas disease is the most prevalent communicable tropical disease in Latin America. The most important vectors are the Triatoma infestans in Argentina, Bolivia, Brazil, Chile, Paraguay, Uruguay and Peru; the R. prolixus in Colombia, Venezuela and Central America; the T. dimidiata in Ecuador and Central America; and the Rhodnius pallescens in Panama.
Source of Infection
Triatomine bugs can infect rodent, marsupials and other wild mammals. These triatomine bugs can also infect domesticated animals such as dogs and cat, and bring the T. cruzi (agent of the disease) inside human dwellings.
The T. cruzi parasites are mainly transmitted by the infected feces of blood-sucking triatomine bugs. These bugs typically found in the Americas, live in the cracks of poorly constructed homes in rural or suburban areas. Normally they hide during the day and become active at night when they feed on blood, including human blood. They usually bite an exposed area of skin or mucosa membranes (lips, conjunctiva, etc.), and the bug defecates close to the bite. The parasites enter the body when the person instinctively smears the bug feces into the bite, and contaminate the eyes, the mouth, or any lesion in the skin.
Although less common T. cruzi can also be transmitted through blood transfusions (20% if the cases) or organ transplant, vertically from an infected mother to child during pregnancy or childbirth (1% of the cases), and by the accidental ingestion of food contaminated with T. cruzi.
Signs and Symptoms
Chagas disease has two clinical forms or phases: an acute phase and a chronic phase. Many people (70- 80% of the infected) are asymptomatic all of their lives, while a 20-30% of the ones infected evolve into the chronic phase, which includes symptoms that indicate damages to the tissue of the heart, digestive system and/ or nerves system.
The acute phase, when it is symptomatic, lasts for about two months after infection. During the acute phase, a high number of parasites circulate in the blood.
Signs and Symptoms for acute Chagas disease can be absent or mild and include the following:
- Signs of entry of the parasite
- Rash and inflammatory nodules (Chagoma)
- Swelling of periorbital soft tissue (Romaña's sign).
- Nausea, diarrhea or vomiting
- Enlarged lymph glands
- Difficulty breathing
- Muscle, abdominal or chest pain.
Although not typical, a first visible sign can be a skin chancre, called chagoma, or a purplish swelling of the lids of one eye. If the infection is left untreated, it can advance into the chronic phase.
A first visible signal can be a skin lesion, called "inoculation chagoma" a regional subcutaneous nodule with adenitis at the site of the bite; and in cases of ocular inoculation, very typical but rare (2% o f acute symptomatic cases) is possible to identify the "sign of Romagna" bipalpebral edema, with retroauricular adenitis. If the infection is not treated, it can progress to the chronic phase.
Over several years or even decades, Chagas disease affects the central nervous system and the enteric nervous system, the digestion system and the heart. Specific medical treatments and surgery may be necessary.
Signs and symptoms for chronic Chagas disease can include the following:
- About 30% of people will develop cardiac damage:
- Heart rhythm abnormalities
- Apical aneurysm.
- Sudden death or heart failure caused by progressive destruction of the heart muscle.
- Less than 10% of patients will experience enlargement of the gastrointestinal tract and organs, and gastrointestinal motor disorders
- Enlargement of the esophagus
- Enlargement of the colon.
- Disturbances of gastric emptying
- Colon and gallbladder motor disorders.
Chagas diagnosis is always clinical, epidemiological and based on laboratory testing (parasitology and serology).
During the acute phase, Chagas disease can be diagnosed through parasitological methods, given the large number of parasites circulating in the blood. In the acute stage, the studies focus on the search and recognition of Trypanosoma cruzi in direct examination and staining of blood smears (methodology: direct parasitological), and in determining the seropostivity of serology tests.
For chronic stage of the disease, Diagnosis is based on clinical assessment, serology and epidemiological history. The definitive diagnosis of T. cruzi infection depends on the positive result of at least two different serologic tests (ELISA, indirect immunofluorescence and indirect hemagglutination) that detect specific antibodies in patient sera.
Prevention and Control
There is no vaccine for the disease Chagas. Integrated vector control is the most effective method of preventing Chagas disease in Latin America, including chemical control by insecticides in infested homes, improvements in houses to prevent vector infestation, personal preventive measures such as bed nets, and informative education and communication to the community about vector-borne diseases.
Serological screening in blood donors is necessary to prevent infection through blood transfusion and organ transplant.
Chagas screening in pregnant women during prenatal care is needed to provide early diagnosis and treatment to newborns and other children of infected mothers.
Good hygiene practices in food preparation, transportation, storage and consumption; screening of blood donors; testing of organ, tissue or cell donors and receivers; and screening
Chagas disease may be etiologically treated in order to eliminate the infection T. cruzi with benznidazole or nifurtimox. If treatment was initiated during the acute phase, both drugs are effective in killing the parasite.
Every infected child should be treated.
Nevertheless, the efficacy of both drugs diminishes the longer a person has been infected, although all patients including chronic cases benefit from improved clinicopathologic changes if treated. Benznidazole and nifurtimox should not be taken by pregnant women.
The potential benefits of medication in chronic cases preventing or delaying the development of Chagas disease should be weighed against the long duration of treatment (up to 2 months), possible adverse reactions (occurring in up to 40% of treated patients), age, comorbidities, and other important characteristics of each patient.
The patients correctly diagnosed patients should receive further medical or surgical, pathophysiological or symptomatic, treatment, specific to each case
PAHO/WHO Sub-regional Initiatives
Chagas disease is associated with multiple social and environmental factors that expose millions of people to infection. Among the main risk factors for Chagas disease are living in poorly constructed housing - particularly in rural and suburban areas - having limited resources, residing in areas of poverty that are socially or economically unstable or have high rates of migration, and belonging to groups linked to seasonal farm work and crop harvests. This disease contributes and perpetuates the cycle of poverty, reduces learning capacity, productivity, and the ability to generate income.
In the early 1990's, the countries affected by Chagas disease, especially those where the disease was endemic, were organized to combat this public health threat. Along with the Pan American Health Organization/ World Health Organization, country representatives generated a successful scheme for horizontal technical cooperation between countries, called the Sub-regional Initiatives for Prevention and Control of Chagas Disease. These initiatives have been developed in the Southern Cone (1992), Central America (1997), Andean countries (1998), Amazonian Countries (2003), and Mexico (2004). These countries have contributed in creating substantial improvements in the situation through the interruption of vector transmission in all or part of the territory of the affected countries, the elimination of exotic species of vectors, the introduction of universal screening of blood donors, the detection of congenital cases, the reduction of prevalence in children, reduction in morbidity, expansion of access to diagnosis and treatment, and improvement of the quality of diagnosis, clinical care, and treatment of infected and ill persons.
The initiatives in the Americas have helped achieve significant reductions in the number of acute cases of disease and the presence of domiciliary triatomine vectors in endemic areas. The estimated number of people infected with T. cruzi worldwide dropped from 30 million in 1990 to 6 to 8 million in 2010. In those 20 years, the annual incidence decreased from 700,000 to 28,000 new cases of infection and the burden of Chagas disease decreased from 2.8 million in 1990-2006 to disability-adjusted life years lost to less than half a million years.
While substantial progress has been made, not all countries have managed to achieve the goals that have been proposed. New challenges have emerged such as the spread of disease due to the migration of people living in endemic countries to non-endemic countries, the need to ensure the sustainability of programs, confronting the emergence or re-emergence of cases of Chagas disease, recovering from natural disasters, expanding coverage of diagnosis and treatment, and achieving universal access to treatment.
Geographical distribution of Chagas disease in the Americas according to the status of transmission by the main vector in each area. Year: 2011.
Achievements in prevention, control, and healthcare of Chagas disease, by Subregion:
- Southern Cone. Interruption of vector transmission of T. cruzi by T. infestans and elimination of vector as a public health threat in Uruguay (1997-2012); interruption of vector transmission of T. cruzi by T. infestans in Chile (1999), Brazil (2006), Paraguay (Eastern Region, 2008, Alto Paraguay, 2013), Argentina (8 provinces between 2001 and 2013), and Bolivia (Department of La Paz and Dpto.de Potosí, 2011 - 2013).
- Central America. Interruption of vector transmission of T. cruzi by R. prolixus in Guatemala (2008), El Salvador (2010), Honduras (2010), Nicaragua (2010). Costa Rica (2010) and Belize (2010). Characterization of transmission from the sylvatic cycle in Panama (2013).
- Andean Region. Interruption of vector transmission of T. cruzi by T. infestans in Peru (Departments of Tacna and Moquegua) and by Rhodnius prolixus in 10 Municipalities in Casanare, Boyacá, Santander and Arauca in Colombia (2013).
- Amazon Region. Surveillance and prevention network in Brazil, Ecuador, Colombia, Guyana, French Guyana and Peru. Response to Chagas outbreaks of foodborne diseases.
- Mexico. Elimination of R. prolixus is certified in Chiapas and Oaxaca.